The most recent trading session ended with Intuitive Surgical, Inc. (ISRG) standing at $403.39, reflecting a +1.25% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a loss of 0.6% for the day. Elsewhere, the Dow saw a downswing of 0.86%, while the tech-heavy Nasdaq depreciated by 1.08%.Coming into today, shares of the company had gained 7.18% in the past month. In that same time, the Medical sector gained 1.32%, while the S&P 500 gained 3.15%.Analysts and inve ...

Industry Overview - The medical technology sector is gaining attention alongside biotechnology, with significant potential for improving patient outcomes [1] - The global medical device technology market was valued at $639.1 billion in 2021 and is projected to reach $953.4 billion by 2027, representing a compound annual growth rate (CAGR) of 7.1% [1] Company Analysis: Johnson & Johnson (JNJ) - Johnson & Johnson operates in both drug manufacturing and medical technology, providing solutions for heart rhythm disorders and neurovascular care [2] - Analysts rate JNJ as a moderate buy with an average price target of $175.21, with a high forecast of $215 per share [2] - In the trailing 12 months, JNJ reported net income of $17.07 billion on revenue of $85.68 billion, with projected earnings per share growth of 7.36% for fiscal 2024 [3] Company Analysis: Intuitive Surgical (ISRG) - Intuitive Surgical specializes in medical instruments and is known for its da Vinci Surgical System, enhancing minimally invasive care [5] - Analysts have a consensus strong buy rating for ISRG, with an average price target of $427.93 and an optimistic target of $475 per share [5] - The company achieved net income of $1.99 billion on sales of $7.32 billion in the trailing 12 months, with expected EPS growth of 10% for fiscal 2024 [6] Company Analysis: Stryker (SYK) - Stryker focuses on orthopedics and spinal business, providing implants for joint replacements and surgical equipment [7] - Analysts rate SYK as a strong buy with an average price target of $382.06, indicating about 14% upside potential [7] - In the trailing 12 months, Stryker reported net income of $3.36 billion on revenue of $20.96 billion, with projected EPS growth of 12.8% for fiscal 2024 [8]

Intuitive Surgical (ISRG) witnessed strong momentum in the year-to-date period. Shares of the company have gained 20% compared with 8.2% growth of the industryin the same time frame. The S&P 500 Composite has risen 11.5% during the same period.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. ISRG’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters with an average ...

In the latest market close, Intuitive Surgical, Inc. (ISRG) reached $404.85, with a +1.62% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.7%. At the same time, the Dow added 0.01%, and the tech-heavy Nasdaq gained 1.1%.Shares of the company witnessed a gain of 6.77% over the previous month, beating the performance of the Medical sector with its gain of 3.27% and the S&P 500's gain of 4.03%.The investment community will be paying close attention to the earnings perfor ...

Brokerage Recommendations and ABR - Intuitive Surgical Inc (ISRG) currently has an Average Brokerage Recommendation (ABR) of 1.70, which approximates between Strong Buy and Buy on a scale of 1 to 5 [1] - The ABR is derived from 23 brokerage firm recommendations, with 14 Strong Buy (60.9%) and 2 Buy (8.7%) ratings [1] - Brokerage recommendations often exhibit a strong positive bias, with firms assigning five Strong Buy recommendations for every Strong Sell recommendation [2] - The ABR should not be confused with Zacks Rank, as the former is based solely on brokerage recommendations while the latter is driven by earnings estimate revisions [4][5] Zacks Rank and Earnings Estimates - Zacks Rank is a proprietary stock rating tool that categorizes stocks into five groups and has a strong track record of predicting near-term stock price movements [3] - The Zacks Rank is updated frequently to reflect changes in earnings estimates, making it a timely indicator of future price movements [5] - Intuitive Surgical has a Zacks Rank 3 (Hold) due to unchanged consensus earnings estimates and other factors related to earnings estimates [6] Investment Considerations for ISRG - The Zacks Consensus Estimate for Intuitive Surgical's current year earnings has remained unchanged at $6.26 over the past month [6] - Analysts' steady views on the company's earnings prospects suggest the stock may perform in line with the broader market in the near term [6] - While the ABR suggests buying Intuitive Surgical, the Zacks Rank indicates a more cautious approach may be prudent [6]

Shares of Intuitive Surgical (ISRG) scaled a new 52-week high of $408.39 on May 22, 2024, before closing the session at $400.90.This Zacks Rank #3 (Hold) company’s shares have risen 18.8% year to date compared with 8.9% growth of the industry. The S&P 500 composite rose 12.1% during the same time frame.Over the past five years, the company’s earnings increased at a CAGR of 6.5% compared with the industry’s 9.9% growth. The company’s long-term growth rate of 16.1% compares with the industry’s 22.5%. Intuitiv ...

Automation continues to be a key driving force of technological innovation in the 21st century. Older industrial sectors have relied on automation for driving efficiencies across the use of various equipment. Technology companies have, of course, employed varying levels of software automation to create new tools and spur productivity. Healthcare services companies have also found a use for automation, particularly in the context of surgery. The robotics sector has been at the epicenter of forces driving aut ...

Summary of Intuitive Surgical, Inc. Conference Call Company Overview - **Company**: Intuitive Surgical, Inc. (NASDAQ: ISRG) - **Event**: BofA Securities 2024 Health Care Conference - **Date**: May 15, 2024 Key Points Industry and Market Dynamics - **Procedure Growth**: Q1 2024 saw a 16% growth in procedures compared to the previous year, which had a 26% growth. The U.S. experienced a 14% growth in procedures, particularly in general surgery and specific areas like cholecystectomy and colon resection [3][4] - **International Growth**: Continued growth in markets such as China, Germany, and the U.K. was noted, indicating a strong international presence [3] Product Launch and Adoption - **da Vinci 5 System**: The company received regulatory approval for the da Vinci 5 system, which is expected to drive future growth. Initial feedback from hospitals has been positive, with surgeons noting improvements in workflow efficiency and visualization [15][20] - **System Placements**: 313 systems were placed in Q1, marking a 14% growth in the installed base. This growth is attributed to strong procedure demand and hospital systems looking to expand capacity [8][10] Financial Guidance and Revenue Streams - **Revenue Expectations**: The company anticipates procedure growth to remain in the range of 14% to 17%. The ASP (Average Selling Price) for da Vinci 5 is expected to be 30% higher than the current Xi system, with a net value increase of about 15% when considering integrated features [21][24] - **Service Revenue**: New digital products, including subscription-based services like case insights, are expected to contribute positively to service revenue. The case insights service aims to enhance surgeon performance through data analytics [29][32] Margin and Cost Management - **Margin Pressures**: The company is facing margin pressures due to supply chain challenges and inflation. However, there are plans to improve margins through increased volume and cost management strategies [54][55] - **Operational Efficiency**: The company aims to leverage investments in IT and infrastructure to improve operational efficiency and reduce SG&A expenses over time [56] Future Outlook - **Market Expansion**: Intuitive Surgical plans to expand its market reach, particularly in price-sensitive regions and community hospitals, as it aims to increase its total addressable market (TAM) from $7 million to $21 million [46][48] - **Long-term Goals**: The company is focused on achieving gross margins of 70% or higher over the medium term, with ongoing efforts to optimize supply chain and product enhancements [55] Additional Insights - **Feedback on da Vinci 5**: Initial feedback indicates that surgeons believe they can perform more procedures in less time with the new system. Features such as integrated insufflation and smoke evacuation have received positive remarks [15][17] - **Trade-in Strategy**: The company has a structured trade-in program for existing systems, which will allow customers to upgrade to da Vinci 5 while recognizing trade-in credits over time [39][40] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Intuitive Surgical's growth prospects, product innovations, and financial strategies.

This company's potential far outweighs its risks.Many companies don't last more than five years; many more have trouble reaching the age of 10. And those that can last 30 years or more are rare. Intuitive Surgical (ISRG 2.61%) is close to accomplishing that sort of longevity.Created in 1995, the medical device specialist hasn't just survived over the years, it has thrived. That's not to say Intuitive Surgical hasn't faced issues, but even with a range of headwinds coming its way, the healthcare pioneer shou ...

More than a half-dozen billionaire money managers pared down their stakes in Nvidia during the December-ended quarter and bought shares of two high-octane artificial intelligence (AI) companies.With few exceptions over the last three decades, investors have always had a next-big-thing investment trend or innovation to look forward to. But since the advent of the internet in the mid-1990s, other next-big-thing trends have consistently come up short. The rise of artificial intelligence (AI) aims to change tha ...